Hemab Therapeutics Holdings, In (COAG) Stock Price & How to Invest

Hemab Therapeutics Holdings (NASDAQ: COAG) is a clinical-stage biotechnology company founded in 2020 with operations in Cambridge, Massachusetts and Denmark. It develops therapies for rare and underserved bleeding disorders. Its lead candidate, sutacimig (HMB-001), is a bispecific antibody in development as a prophylactic treatment for Glanzmann thrombasthenia (which has a Breakthrough Therapy Designation) and Factor VII deficiency, with additional programs targeting von Willebrand disease (HMB-002) and heavy menstrual bleeding (HMB-003). The company has roughly 59 employees and no approved products or meaningful product revenue. In September 2026 it dosed the first participant in a Phase 1 trial of HMB-003.

The investment picture is a classic clinical-stage biotech profile: no commercial sales, ongoing net losses (about $83 million over the trailing twelve months), and a valuation (~$1.45 billion market cap on October 16, 2026) built on the expected future value of its pipeline rather than current fundamentals. Hemab completed a NASDAQ IPO in May 2026 at $18 per share, raising roughly $347 million in gross proceeds. The stock climbed as high as about $55 over the summer, then gave back much of that gain, falling about 25% in the past month alone without a company-specific setback in the news flow. Q2 2026 brought a net loss of about $24 million, or $0.80 per share against a $0.82 estimate, and the company held about $457 million of cash at June 30. Analysts remain positive: six covering it carry an average target near $63, and JPMorgan initiated coverage on October 15 at Overweight with a $70 target. Management says its cash position funds operations into 2029, so financing pressure is low in the near term, but returns from here depend heavily on binary trial and regulatory outcomes over the next few years.

As a pre-revenue clinical-stage biotech, COAG carries substantial risk and its value depends on trial outcomes that are inherently binary. A failed or delayed Phase 3 readout for sutacimig could sharply reduce the stock, since no approved products or sales cushion the downside. The company continues to post net losses and will need commercial success (or further capital raises) to sustain itself beyond its stated runway into 2029. The stock has already shown how volatile it can be, swinging between about $23 and $55 in its first five months and falling about 36% over the three months to October 16, 2026; it still trades above its $18 IPO price, so optimism remains embedded, and small, recently listed biotechs can be thinly followed. Regulatory setbacks, competitive therapies, or safety findings could each materially impair the thesis.

6 analysts publish price targets on COAG, averaging $62.67 against a $30.07 price as of October 2026, or +108.4%. The published targets run from $58.00 to $70.00, a narrow spread, and the ratings split 6 buy, 0 hold, 0 sell. Over the last six months there have been 5 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full COAG forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Hemab Therapeutics Holdings, In. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Sutacimig lead program. Sutacimig (HMB-001) is the value anchor, carrying a Breakthrough Therapy Designation in Glanzmann thrombasthenia with a Phase 3 trial planned for the second half of 2026. The most optimistic published target, $70.00, assumes this works close to its best case.

The case against. As a pre-revenue clinical-stage biotech, COAG carries substantial risk and its value depends on trial outcomes that are inherently binary. The most pessimistic target, $58.00, is roughly what COAG is worth if this bites instead.

Read the full bull and bear case on COAG, including what would have to change to break either one. Walnut is not an investment adviser.

No. Hemab Therapeutics Holdings, In (COAG) has not split its stock in the last 10 years. That is a statement about the window we check rather than about the company’s entire history, so an older split is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Hemab Therapeutics Holdings, In's investor relations page or your broker.

• Market cap: ~$1.45B
• Share price: ~$31 (Oct 16, 2026)
• Product revenue (TTM): ~$0 (pre-commercial)
• Net loss (TTM): ~-$83M
• EPS (Q2 2026): -$0.80 vs -$0.82 est.
• Cash (June 30, 2026): ~$457M (runway into 2029)
• Analyst mean target: ~$63 (6 analysts)
• IPO (May 2026): ~$18/share, ~$347M gross

COAG has no meaningful product revenue and is valued on the expected future worth of its pipeline, not on earnings, so standard metrics like P/E do not apply. Its roughly $1.45 billion market cap sits against trailing net losses of about $83 million and about $457 million of cash, so the market assigns roughly $1 billion of value to the pipeline itself. The price-to-book ratio is about 3.2, down from a far richer level in July, and the average analyst target of about $63 is roughly double the current price. Third-quarter results are expected around mid-November 2026.

Other names that sit close to COAG: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get COAG exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so COAG sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where COAG fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

COAG is a well-funded but pre-revenue clinical-stage biotech whose value rests almost entirely on the outcome of its bleeding-disorder trials.

Whether COAG is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is COAG a buy or a sell?, and where the stock could go from here in the COAG stock forecast.

For income investors, whether COAG pays a dividend and how the payout looks is covered in does COAG pay a dividend? And to weigh COAG against a peer, read the full side-by-side comparisons: COAG vs NVO and COAG vs SNY.